These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 29125762)
1. Highly Selective Dopamine D Reilly SW; Griffin S; Taylor M; Sahlholm K; Weng CC; Xu K; Jacome DA; Luedtke RR; Mach RH J Med Chem; 2017 Dec; 60(23):9905-9910. PubMed ID: 29125762 [TBL] [Abstract][Full Text] [Related]
2. Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D Reilly SW; Riad AA; Hsieh CJ; Sahlholm K; Jacome DA; Griffin S; Taylor M; Weng CC; Xu K; Kirschner N; Luedtke RR; Parry C; Malhotra S; Karanicolas J; Mach RH J Med Chem; 2019 May; 62(10):5132-5147. PubMed ID: 31021617 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of N-phenyl homopiperazine analogs as potential dopamine D3 receptor selective ligands. Li A; Mishra Y; Malik M; Wang Q; Li S; Taylor M; Reichert DE; Luedtke RR; Mach RH Bioorg Med Chem; 2013 Jun; 21(11):2988-98. PubMed ID: 23618707 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D Kumar V; Moritz AE; Keck TM; Bonifazi A; Ellenberger MP; Sibley CD; Free RB; Shi L; Lane JR; Sibley DR; Newman AH J Med Chem; 2017 Feb; 60(4):1478-1494. PubMed ID: 28186762 [TBL] [Abstract][Full Text] [Related]
5. High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice. Boateng CA; Bakare OM; Zhan J; Banala AK; Burzynski C; Pommier E; Keck TM; Donthamsetti P; Javitch JA; Rais R; Slusher BS; Xi ZX; Newman AH J Med Chem; 2015 Aug; 58(15):6195-213. PubMed ID: 26203768 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and preliminary bioactivity evaluation of bitopic benzopyranomorpholine analogues as selective dopamine D3 receptor ligands as anti-drug addiction therapeutic agents. Cai J; Huang M; Wang Y; Chen X; Ji M Bioorg Med Chem Lett; 2021 Sep; 48():128269. PubMed ID: 34284107 [TBL] [Abstract][Full Text] [Related]
7. Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand. Rangel-Barajas C; Malik M; Taylor M; Neve KA; Mach RH; Luedtke RR J Neurochem; 2014 Nov; 131(4):418-31. PubMed ID: 25041389 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity. Ananthan S; Saini SK; Zhou G; Hobrath JV; Padmalayam I; Zhai L; Bostwick JR; Antonio T; Reith ME; McDowell S; Cho E; McAleer L; Taylor M; Luedtke RR J Med Chem; 2014 Aug; 57(16):7042-60. PubMed ID: 25126833 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145 [TBL] [Abstract][Full Text] [Related]
10. 1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists. Micheli F; Bacchi A; Braggio S; Castelletti L; Cavallini P; Cavanni P; Cremonesi S; Dal Cin M; Feriani A; Gehanne S; Kajbaf M; Marchió L; Nola S; Oliosi B; Pellacani A; Perdonà E; Sava A; Semeraro T; Tarsi L; Tomelleri S; Wong A; Visentini F; Zonzini L; Heidbreder C J Med Chem; 2016 Sep; 59(18):8549-76. PubMed ID: 27564135 [TBL] [Abstract][Full Text] [Related]
11. Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists. Furman CA; Roof RA; Moritz AE; Miller BN; Doyle TB; Free RB; Banala AK; Paul NM; Kumar V; Sibley CD; Newman AH; Sibley DR Eur Neuropsychopharmacol; 2015 Sep; 25(9):1448-61. PubMed ID: 25583363 [TBL] [Abstract][Full Text] [Related]
12. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. Newman AH; Beuming T; Banala AK; Donthamsetti P; Pongetti K; LaBounty A; Levy B; Cao J; Michino M; Luedtke RR; Javitch JA; Shi L J Med Chem; 2012 Aug; 55(15):6689-99. PubMed ID: 22632094 [TBL] [Abstract][Full Text] [Related]
13. Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists. Bettinetti L; Schlotter K; Hübner H; Gmeiner P J Med Chem; 2002 Oct; 45(21):4594-7. PubMed ID: 12361386 [TBL] [Abstract][Full Text] [Related]
14. Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment. Kumar V; Bonifazi A; Ellenberger MP; Keck TM; Pommier E; Rais R; Slusher BS; Gardner E; You ZB; Xi ZX; Newman AH J Med Chem; 2016 Aug; 59(16):7634-50. PubMed ID: 27508895 [TBL] [Abstract][Full Text] [Related]
15. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of arylpiperazine-reverse amides as biased dopamine D3 receptor ligands. Cao Y; Paudel S; Zhang X; Kim KM; Cheon SH Bioorg Med Chem; 2015 Sep; 23(17):5264-72. PubMed ID: 26278029 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of structurally constrained hybrid analogues containing ropinirole moiety as a novel class of potent and selective dopamine D3 receptor ligands. Zhou B; Hong KH; Ji M; Cai J Chem Biol Drug Des; 2018 Sep; 92(3):1597-1609. PubMed ID: 29710404 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and evaluation of bitopic arylpiperazinephenyl-1,2,4-oxadiazoles as preferential dopamine D3 receptor ligands. Cao Y; Min C; Acharya S; Kim KM; Cheon SH Bioorg Med Chem; 2016 Jan; 24(2):191-200. PubMed ID: 26707842 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound. Vangveravong S; Zhang Z; Taylor M; Bearden M; Xu J; Cui J; Wang W; Luedtke RR; Mach RH Bioorg Med Chem; 2011 Jun; 19(11):3502-11. PubMed ID: 21536445 [TBL] [Abstract][Full Text] [Related]
20. Investigation of Novel Primary and Secondary Pharmacophores and 3-Substitution in the Linking Chain of a Series of Highly Selective and Bitopic Dopamine D Shaik AB; Kumar V; Bonifazi A; Guerrero AM; Cemaj SL; Gadiano A; Lam J; Xi ZX; Rais R; Slusher BS; Newman AH J Med Chem; 2019 Oct; 62(20):9061-9077. PubMed ID: 31526003 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]